EXHIBIT 1

```
Page 1
 1
                      MISSOURI CIRCUIT COURT
 2
                   TWENTY-FIRST JUDICIAL CIRCUIT
 3
                         ST. LOUIS COUNTY
 4
                                              CERTIFIED COPY
 5
      EDWIN SPIRER, et al.,
                                 )
 6
            Plaintiffs,
                                 ) Case No. 12SL-CC01263
 7
     V.
                                  ) Division 20
      MONSANTO COMPANY, et al.,
 8
 9
            Defendants.
                                 )
10
11
           VIDEO DEPOSITION of DAVID O. CARPENTER, M.D.
12
13
                         Albany, New York
14
                         December 17, 2015
15
16
17
18
19
20
21
22
23
24
     Reported by: Dana Welch, CSR, RPR, CRR
25
     Job No: 100731
```

		Page 2
1		
2		
3		
4		
5	December 17, 2015	
6	8:58 a.m.	
7		
8		·
9	Video deposition of DAVID O. CARPENTER,	
10	M.D., held at Hilton Albany, 40 Lodge Street,	
11	Albany, New York, before Dana Welch, Certified	
12	Shorthand Reporter, Registered Professional	
13	Reporter, and Certified Realtime Reporter.	
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

```
Page 275
 1
                             CARPENTER
 2
              MR. MILLER: I move to strike as being
 3
      nonresponsive.
              MR. STEWART: Adam, you have about two
 5
      minutes. Just letting you know.
 6
              MR. MILLER: All right.
              Doctor, in the conclusion in section 6.1
 8
      of the monograph -- well -- well, let me do this.
               (Exhibit 17, PLTEXP039416 - 039417,
 9
10
          Carcinogenicity of polychlorinated biphenyls
11
          and polybrominated biphenyls, marked for
12
          identification.)
13
      BY MR. MILLER:
14
              Here, let me mark Exhibit 17.
15
      Carcinogenicity of polychlorinated biphenyls and
16
      polybrominated biphenyls. This is the report that
17
      was published in the Lancet Oncology --
18
              MR. STEWART: What's the exhibit number.
19
              MS. SCHNALL: 17.
20
          Q.
              -- following the working group meeting?
21
          Α.
              Correct.
22
         Q. If you look on page 288, it's a carryover
     from 287 regarding strength of the association
23
24
     between PCBs and human cancers. And it reads.
25
      "Increased risks for non-Hodgkin lymphoma and
```

```
Page 276
 1
                            CARPENTER
      breast cancer were also reported, both of which
 3
      were biologically plausible. However, the
      associations were not consistent and were
 4
     considered as providing limited evidence. "
 5
 6
             I read that correctly?
 7
         A. Correct.
          Q. Was that, in fact, the conclusion of the
 8
 9
     IARC working group at the conclusion of the meeting
     that you attended in Lyon, France?
10
11
         A. That wording is the standard wording for
     IARC monographs where they consider that there's
12
     strong evidence, but not strong enough to say that
13
14
     they can conclude causation.
15
              (Transcript continued onto following page
16
17
      to accommodate jurat. Nothing omitted.)
18
19
20
21
22
23
24
25
```

		Page	278
1	CERTIFICATE		
2			
3			
4	I, Dana Welch, Certified Shorthand Reporter,		
5	Registered Professional Reporter, Certified		
6	Realtime Reporter and Notary Public, do hereby		
7	certify that DAVID CARPENTER, M.D., the witness		
8	whose deposition is hereinbefore set forth, was		
9	duly sworn by me and that such deposition is a true		
10	record of the testimony given by the witness.		
11	I further certify that I am neither related		
12	to nor employed by any of the parties in or counsel		
1,3	to this action, nor am I financially interested in		
14	the outcome of this action.		
15	In witness whereof, I have hereunto set my		
16	hand this 18th day of December, 2015.		
17			
1.8	Dana Welch CSR, RPR, CRR,		
19	Dalia Welcir Car, Crr,		
20			
21			
22			
23			
24			
25			
			1